{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T10:02:33Z","timestamp":1768644153356,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science"},{"name":"ICT"},{"name":"Future Planning","award":["2012M3A9B6055200"],"award-info":[{"award-number":["2012M3A9B6055200"]}]},{"name":"Future Planning","award":["2015R1A2A1A15054252"],"award-info":[{"award-number":["2015R1A2A1A15054252"]}]},{"name":"National R&D Program for Cancer Control"},{"name":"Korean Ministry for Health and Welfare","award":["0720520"],"award-info":[{"award-number":["0720520"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.ymthe.2016.11.005","type":"journal-article","created":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T16:48:54Z","timestamp":1487782134000},"page":"356-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement"],"prefix":"10.1016","volume":"25","author":[{"given":"Sung Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bitna","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Sook","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong-Wook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2016.11.005_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2016.11.005_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0898-6568(00)00084-X","article-title":"The importance of being K-Ras","volume":"12","author":"Ellis","year":"2000","journal-title":"Cell Signal."},{"key":"10.1016\/j.ymthe.2016.11.005_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2016.11.005_bib4","first-page":"127","article-title":"K-ras as a target for cancer therapy","volume":"1756","author":"Friday","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymthe.2016.11.005_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/1947601912460547","article-title":"KRAS testing: A tool for the implementation of personalized medicine","volume":"3","author":"Shackelford","year":"2012","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ymthe.2016.11.005_bib6","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1054\/bjoc.2001.1964","article-title":"Kirsten ras mutations in patients with colorectal cancer: the \u2018RASCAL II\u2019 study","volume":"85","author":"Andreyev","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ymthe.2016.11.005_bib7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/carcin\/bgp094","article-title":"The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras","volume":"30","author":"Tsang","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ymthe.2016.11.005_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1947601911411084","article-title":"Ras in cancer and developmental diseases","volume":"2","author":"Fern\u00e1ndez-Medarde","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.ymthe.2016.11.005_bib9","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2016.11.005_bib10","first-page":"1743","article-title":"Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct","volume":"53","author":"Georges","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2016.11.005_bib11","first-page":"900","article-title":"Suppression of the neoplastic phenotype in\u00a0vivo by an anti-ras ribozyme","volume":"54","author":"Kashani-Sabet","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2016.11.005_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1389201043376689","article-title":"Anti-genes: siRNA, ribozymes and antisense","volume":"5","author":"Scanlon","year":"2004","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nchembio.362","article-title":"Small-molecule inhibition of APT1 affects Ras localization and signaling","volume":"6","author":"Dekker","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc3151","article-title":"Targeting protein prenylation for cancer therapy","volume":"11","author":"Berndt","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2016.11.005_bib15","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nm0696-668","article-title":"Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase","volume":"2","author":"Monia","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2016.11.005_bib16","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/10533","article-title":"Blockade of the MAP kinase pathway suppresses growth of colon tumors in\u00a0vivo","volume":"5","author":"Sebolt-Leopold","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2016.11.005_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1158\/1541-7786.MCR-04-0206","article-title":"Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy","volume":"3","author":"Fleming","year":"2005","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ymthe.2016.11.005_bib18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1349-7006.2007.00506.x","article-title":"K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment","volume":"98","author":"R\u00e9jiba","year":"2007","journal-title":"Cancer Sci."},{"issue":"1, Suppl 1","key":"10.1016\/j.ymthe.2016.11.005_bib19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.seminoncol.2003.12.012","article-title":"Farnesyltransferase inhibitors","volume":"31","author":"Sebti","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(04)01565-7","article-title":"Molecular therapy in pancreatic adenocarcinoma","volume":"5","author":"MacKenzie","year":"2004","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/1535-7163.MCT-10-0750","article-title":"Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy","volume":"10","author":"Sunaga","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2016.11.005_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/371619a0","article-title":"Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing","volume":"371","author":"Sullenger","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2016.11.005_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nm0696-643","article-title":"Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells","volume":"2","author":"Jones","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2016.11.005_bib24","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1006\/jmbi.1998.2447","article-title":"Trans-splicing ribozymes for targeted gene delivery","volume":"285","author":"K\u00f6hler","year":"1999","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib25","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/328596a0","article-title":"A small catalytic oligoribonucleotide","volume":"328","author":"Uhlenbeck","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2016.11.005_bib26","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1126\/science.280.5369.1593","article-title":"Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors","volume":"280","author":"Lan","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2016.11.005_bib27","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ng0498-378","article-title":"Ribozyme-mediated trans-splicing of a trinucleotide repeat","volume":"18","author":"Phylactou","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2016.11.005_bib28","doi-asserted-by":"crossref","first-page":"8490","DOI":"10.1073\/pnas.150104097","article-title":"Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts","volume":"97","author":"Watanabe","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2016.11.005_bib29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1172\/JCI200216481","article-title":"Functional repair of a mutant chloride channel using a trans-splicing ribozyme","volume":"110","author":"Rogers","year":"2002","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2016.11.005_bib30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ymthe.2004.05.007","article-title":"Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA","volume":"10","author":"Shin","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2016.11.005_bib31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S1525-0016(02)00063-1","article-title":"Ribozyme-mediated selective induction of new gene activity in hepatitis C virus internal ribosome entry site-expressing cells by targeted trans-splicing","volume":"7","author":"Ryu","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2016.11.005_bib32","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ymthe.2005.06.096","article-title":"Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript","volume":"12","author":"Kwon","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2016.11.005_bib33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/1078-0432.CCR-07-1524","article-title":"Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model","volume":"14","author":"Jeong","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2016.11.005_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/cgt.2008.64","article-title":"Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in\u00a0vivo","volume":"16","author":"Song","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2016.11.005_bib35","doi-asserted-by":"crossref","first-page":"12315","DOI":"10.1038\/srep12315","article-title":"Targeted regression of hepatocellular carcinoma by cancer-specific RNA replacement through microRNA regulation","volume":"5","author":"Kim","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2016.11.005_bib36","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.25988","article-title":"Selective and efficient retardation of cancers expressing cytoskeleton-associated protein 2 by targeted RNA replacement","volume":"129","author":"Ban","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2016.11.005_bib37","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1073\/pnas.93.5.1831","article-title":"Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins","volume":"93","author":"Mesnil","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2016.11.005_bib38","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ijc.10701","article-title":"Ectopic expression of herpes simplex virus-thymidine kinase gene in human non-small cell lung cancer cells conferred caspase-activated apoptosis sensitized by ganciclovir","volume":"102","author":"Chiu","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ymthe.2016.11.005_bib39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/107327480401100105","article-title":"Molecular-targeted agents in pancreatic cancer","volume":"11","author":"Saad","year":"2004","journal-title":"Cancer Control."},{"key":"10.1016\/j.ymthe.2016.11.005_bib40","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1261\/rna.5450203","article-title":"Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes","volume":"9","author":"Byun","year":"2003","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2016.11.005_bib41","doi-asserted-by":"crossref","first-page":"26522","DOI":"10.1016\/S0021-9258(19)74344-0","article-title":"The influence of 5\u2032-secondary structures upon ribosome binding to mRNA during translation in yeast","volume":"268","author":"Sagliocco","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2016.11.005_bib42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/nbt0997-902","article-title":"Evaluating and enhancing ribozyme reaction efficiency in mammalian cells","volume":"15","author":"Jones","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib43","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1158\/1535-7163.MCT-14-0074","article-title":"Therapeutic silencing of KRAS using systemically delivered siRNAs","volume":"13","author":"Pecot","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ymthe.2016.11.005_bib44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","article-title":"A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival","volume":"15","author":"Singh","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2016.11.005_bib45","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2159-8290.CD-12-0231","article-title":"Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling","volume":"3","author":"Young","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2016.11.005_bib46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab","volume":"26","author":"Li\u00e8vre","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib47","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdm496","article-title":"KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab","volume":"19","author":"De Roock","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib48","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib49","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/onc.2010.430","article-title":"Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab","volume":"30","author":"Dunn","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.ymthe.2016.11.005_bib50","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.2009.21.9170","article-title":"American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy","volume":"27","author":"Allegra","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib51","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.2009.24.6116","article-title":"Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer","volume":"28","author":"Bardelli","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2016.11.005_bib52","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jconrel.2015.10.009","article-title":"Polymeric oncolytic adenovirus for cancer gene therapy","volume":"219","author":"Choi","year":"2015","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2016.11.005_bib53","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2016.11.005_bib54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7150\/thno.13621","article-title":"Image-aided suicide gene therapy utilizing multifunctional hTERT-targeting adenovirus for clinical translation in hepatocellular carcinoma","volume":"6","author":"Kim","year":"2016","journal-title":"Theranostics"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616453888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616453888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T15:59:54Z","timestamp":1658678394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616453888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1525001616453888"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2016.11.005","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2016.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}